Kasugamycin A, its preparation method and application

By isolating and purifying kasugamycin A from the root of Ligustrum lucidum, the problem of the lack of immune-enhancing active compounds in the existing technology has been solved, and significant promotion of cytokine secretion has been achieved, making it suitable for a variety of immune-enhancing drug formulations.

CN123106794APending Publication Date: 2026-11-17QIQIHAR MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611285265.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current technology has not provided in-depth research on the chemical composition of Ligustrum lucidum, lacking compounds with immune-enhancing activity, making it difficult to effectively regulate the function of the immune system.

Method used

The root of *Ligustrum lucidum* was isolated and purified using methods such as 70% ethanol extraction, macroporous adsorption resin, ODS column chromatography, and preparative liquid chromatography, and then formulated into an immune-enhancing drug.

Benefits of technology

Kasugamycin A can significantly promote the secretion of NO, IL-6 and TNF-α by RAW 264.7 cells, showing good immune-enhancing activity. It is suitable for the preparation of various dosage forms such as injections, lyophilized powder injections, and oral preparations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106794A_ABST
    Figure CN123106794A_ABST
Patent Text Reader

Abstract

This invention relates to a substance with in vitro immunomodulatory activity, its preparation method, and its application. The novel substance with in vitro immunomodulatory activity, its preparation method, and its application are described. The kasugamochrome glycoside A has the molecular formula C2. 22 H 28 O 13 Methods: 1. Extract the root of *Ligustrum lucidum* using 70% ethanol (v / v) as an aqueous solvent; 2. Disperse the concentrated extract after removing ethanol by rotary evaporation with water and load it onto a D101 macroporous resin column; 3. Elute the fraction with 60% ethanol (v / v) from the macroporous resin, and then separate and purify it by silica gel column chromatography and preparative high-performance liquid chromatography to obtain the product. *Ligustrum lucidum* chromone A is used to prepare immunomodulatory drugs. In this invention, *Ligustrum lucidum* chromone A at concentrations of 3.125 μM, 6.25 μM, and 12.5 μM increased NO secretion by 25.0%, 1431.3%, and 2350.0%, respectively; increased IL-6 secretion by 17.6%, 38.9%, and 92.9%, respectively; and increased TNF-α secretion by 89.8%, 170.6%, and 246.4%, respectively. This indicates that it has good immunomodulatory activity. This invention belongs to the field of extraction of effective components from natural drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a novel substance with in vitro immune-enhancing activity, its method, and its application. Background Technology

[0002] Dianella ensifolia (L.) DC., a plant belonging to the genus Dianella in the Liliaceae family, is the dried root of a plant commonly used in traditional Chinese medicine by the Lahu ethnic group. It is also known as Shanjianlan, Shanjiaojian, and Shanmaoer. It is mainly produced in Yunnan, Guangdong, Guizhou, Sichuan, Guangxi, and Fujian provinces of my country, and is also distributed in tropical Asian regions. It has a sweet and pungent taste, and is cool in nature, possessing detoxifying, swelling-reducing, and analgesic properties. In folk medicine, it is ground into powder, mixed with a suitable amount of vinegar, and applied externally to treat boils, abscesses, tinea, lymphadenitis, and other diseases. Currently, research on the chemical composition of Dianella ensifolia is not yet in-depth. Its main structural types include flavanones, chromones, naphthyl glycosides, and resorcinols, which possess whitening, anti-tumor, antioxidant, and immunomodulatory biological activities, making it a valuable source of herbal medicine.

[0003] The regulation of the immune system relies on a complex signal transduction network, in which immune mediators (including cytokines, chemokines, and adhesion molecules) play a central role. When antigen-presenting cells recognize external stimuli, they initiate a cascade reaction to secrete various immunomodulatory factors. These signaling molecules precisely regulate the differentiation direction and functional state of lymphocytes by binding to specific receptors on the surface of target cells, thereby maintaining the appropriateness and specificity of the immune response. In the innate immune system, macrophages are important effector cells, responsible for phagocytizing and clearing pathogens, and coordinating the immune response process by secreting immune mediators such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). The RAW 264.7 mouse macrophage line, due to its stable proliferative characteristics and mature immune function, has become a standardized tool for studying immune activation mechanisms. The secretion levels of nitric oxide (NO) and various cytokines in activated RAW264.7 macrophages change. NO is an important immune-active substance that promotes activated macrophage function and plays a crucial role in regulating the overall immune response. Cytokine secretion also plays a vital role in the immune response. Summary of the Invention

[0004] The purpose of this invention is to provide a novel compound with in vitro immune-enhancing activity, its preparation method, and its application.

[0005] Kassaponin A, wherein the molecular formula of Kassaponin A is C 22 H 28 O 13 The molecular structural formula is:

[0006] The molecular weight is 500.5.

[0007] The preparation method of the kasugamycin glycoside A is as follows:

[0008] 1. Place the root of *Ligustrum lucidum* in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and reflux extract with 70% ethanol for 2 hours each time, for 3 times, and combine the extracts to obtain the extract;

[0009] 2. Concentrate the extract obtained in step 1 until there is no alcohol odor, dilute it with water, and then load it onto a D101 macroporous resin column. Then, elute it sequentially with water, 15% (v / v), 30% (v / v), 60% (v / v) and 90% (v / v) ethanol aqueous solution.

[0010] 3. The elution fraction of the 60% ethanol aqueous solution from step 2 was separated by ODS column chromatography. Elution was carried out sequentially with methanol-water solutions of 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% concentrations to obtain methanol-water eluents of different concentrations. The elution fraction of 40% methanol-water eluent from the ODS column chromatography was used to prepare a high-performance liquid chromatography (HPLC) sample. The HPLC chromatogram was prepared using 28% methanol as the mobile phase and a flow rate of 3 mL / min. The absorption peak appearing at the retention time of 23-24 min was collected, which yielded sambroside A.

[0011] Furthermore, the pressure of the Soxhlet dynamic extraction and concentration unit described in step one is set to ambient temperature and pressure extraction.

[0012] Furthermore, the high-performance liquid chromatography (HPLC) chromatograms described in step three were acquired using a Waters 2535 semi-preparative HPLC system, with C0.05... 18 The reversed-phase silica gel column was used as the packing material, and the Waters 2998 DAD detector was used as the detector.

[0013] The kasugamycin A is used to prepare an immune-enhancing drug.

[0014] Furthermore, the dosage forms of the immune-enhancing drugs include injections, lyophilized powder injections, and oral preparations.

[0015] Furthermore, the oral formulations include tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release formulations.

[0016] Furthermore, the kasugamycin A, as an active ingredient in an immune-enhancing drug, is used to promote the secretion of NO, IL-6, and TNF-α by RAW 264.7 cells.

[0017] The chemical name of the safflower glycoside A of this invention is 6-O-[β-D-xylopyranosyl-(1→6)-β-D-glucopyranosyl]-5-hydroxy-2,7-dimethyl-4H-1-benzopyran-4-one, and its molecular formula is C1. 22 H 28 O 13 .

[0018] The compounds described in this invention can be formulated into pharmaceutically acceptable solid or liquid formulations by adding pharmaceutically acceptable excipients.

[0019] Beneficial effects: Compared with the prior art, the present invention has the following advantages:

[0020] This invention provides a new compound derived from *Ligustrum lucidum* and a method for extracting, separating, and purifying the new compound. The method employs 70% ethanol extraction, macroporous adsorption resin, ODS column chromatography, and preparative liquid chromatography to successfully obtain the new compound. The operation method is simple and rapid, and the compound obtained by this method has high purity. Furthermore, studies have shown that the above compound has immune-enhancing activity.

[0021] This novel compound promotes the secretion of NO, IL-6, and TNF-α in RAW 264.7 cells. At concentrations of 3.125 μM, 6.25 μM, and 12.5 μM, the compound increased NO secretion by 25.0%, 1431.3%, and 2350.0%, respectively; IL-6 secretion by 17.6%, 38.9%, and 92.9%, respectively; and TNF-α secretion by 89.8%, 170.6%, and 246.4%, respectively. This indicates that it possesses good immunomodulatory activity. The kasugamycin A of this invention can be formulated into anti-inflammatory drugs such as injections, lyophilized powder injections, infusions, or oral preparations (including tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release formulations). Attached Figure Description

[0022] Figure 1 The MS spectrum of the kasugamycin A prepared in this invention;

[0023] Figure 2 The kasugamycin A prepared in this invention 1 H-NMR spectrum;

[0024] Figure 3 The kasugamycin A prepared in this invention 13 C-NMR spectrum;

[0025] Figure 4 Figure showing the effect of kasugamycin A on cell proliferation as tested by CCK-8 assay;

[0026] Figure 5 A standard curve for NO testing using the Griess colorimetric method;

[0027] Figure 6 Figure showing the effect of kasugamycin A on NO secretion by cells as determined by the Griess colorimetric assay.

[0028] Figure 7 A standard curve for IL-6 testing using the ELISA method;

[0029] Figure 8 Figure showing the effect of kasugamycin A on IL-6 secretion by cells as determined by ELISA.

[0030] Figure 9 A standard curve for TNF-α testing using the ELISA method;

[0031] Figure 10 The figure shows the effect of sagofloxacin A on TNF-α secretion by cells as determined by ELISA. Detailed Implementation

[0032] The technical solution of the present invention is not limited to the specific embodiments listed below, but also includes any combination of the specific embodiments.

[0033] Specific Implementation Method 1: This implementation method uses kasugamoside A, wherein the molecular formula of kasugamoside A is C 22 H 28 O 13 The molecular structural formula is:

[0034] The molecular weight is 500.5.

[0035] Specific Implementation Method Two: The preparation method of kasugamycin A described in Specific Implementation Method One is as follows:

[0036] 1. Place the root of *Ligustrum lucidum* in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and reflux extract with 70% ethanol for 2 hours each time, for 3 times, and combine the extracts to obtain the extract;

[0037] 2. Concentrate the extract obtained in step 1 until there is no alcohol odor, dilute it with water, and then load it onto a D101 macroporous resin column. Then, elute it sequentially with water, 15% (v / v), 30% (v / v), 60% (v / v) and 90% (v / v) ethanol aqueous solution.

[0038] 3. The elution fraction of the 60% ethanol aqueous solution from step 2 was separated by ODS column chromatography. Elution was carried out sequentially with methanol-water solutions of 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% concentrations to obtain methanol-water eluents of different concentrations. The elution fraction of 40% methanol-water eluent from the ODS column chromatography was used to prepare a high-performance liquid chromatography (HPLC) sample. The HPLC chromatogram was prepared using 28% methanol as the mobile phase and a flow rate of 3 mL / min. The absorption peak appearing at the retention time of 23-24 min was collected, which yielded sambroside A.

[0039] Specific Implementation Method 3: This implementation method differs from Specific Implementation Method 2 in that the pressure of the Soxhlet dynamic extraction and concentration unit described in step 1 is set to atmospheric pressure extraction, and the extraction temperature is room temperature. Everything else is the same as in Specific Implementation Method 2.

[0040] Specific Implementation Method Four: This implementation method differs from Specific Implementation Methods Two or Three in that the high-performance liquid chromatography (HPLC) chromatograms described in step three are acquired using a Waters 2535 semi-preparative HPLC system, with C0.05 as the standard value. 18 The reversed-phase silica gel column is used as the packing material, and a Waters 2998 DAD detector is used as the detector. Everything else is the same as in specific embodiments two or three.

[0041] Specific Implementation Method 5: The kasugamycin A described in Specific Implementation Methods 1 to 4 is used as an active ingredient in the preparation of immune-enhancing drugs.

[0042] Specific Implementation Method Six: This implementation method differs from Specific Implementation Method Five in that the dosage form of the immune-enhancing drug includes injections, lyophilized powder injections, and oral preparations. Everything else is the same as in Specific Implementation Method Five.

[0043] Specific Implementation Method Seven: This implementation method differs from Specific Implementation Method Six in that the oral preparations include tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release preparations. Everything else is the same as in Specific Implementation Method Six.

[0044] Specific Implementation Method Eight: This implementation method differs from Specific Implementation Methods Five to Seven in that the kasugamycin A is used as the active ingredient of the immune-enhancing drug to promote the release of NO, IL-6, and TNF-α from RAW 264.7. Everything else is the same as in Specific Implementation Methods Five to Seven.

[0045] The following experiments were used to verify the effectiveness of the invention:

[0046] Experiment 1:

[0047] Kassaponin A, wherein the molecular formula of Kassaponin A is C22 H 28 O 13 The molecular structural formula is:

[0048] The molecular weight is 500.5.

[0049] The preparation method of the kasugamycin glycoside A is as follows:

[0050] 1. Place the root of *Ligustrum lucidum* in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and reflux extract with 70% ethanol for 2 hours each time, for 3 times, and combine the extracts to obtain the extract;

[0051] 2. Concentrate the extract obtained in step 1 until there is no alcohol odor, dilute it with water, and then load it onto a D101 macroporous resin column. Then, elute it sequentially with water, 15% (v / v), 30% (v / v), 60% (v / v) and 90% (v / v) ethanol aqueous solution.

[0052] 3. The elution fraction of the 60% ethanol aqueous solution from step 2 was separated by ODS column chromatography. Elution was carried out sequentially with methanol-water solutions of 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% concentrations to obtain methanol-water eluents of different concentrations. The elution fraction of 40% methanol-water eluent from the ODS column chromatography was used to prepare a high-performance liquid chromatography (HPLC) sample. The HPLC chromatogram was prepared using 28% methanol as the mobile phase and a flow rate of 3 mL / min. The absorption peak appearing at the retention time of 23-24 min was collected, which yielded sambroside A.

[0053] The pressure of the Soxhlet dynamic extraction and concentration unit described in step one is set to normal temperature and pressure extraction.

[0054] Step 3, the preparative high-performance liquid chromatography (HPLC) was performed using a Waters 2535 semi-preparative HPLC system, a Waters 2998 DAD detector, and a C13 column. 18 Reversed silica gel, mobile phase (methanol:water = 28:72), flow rate 3 ml / min.

[0055] This experiment used 1.5 kg of dried *Ligustrum lucidum* to obtain 49.8 mg of *Ligustrum lucidum* chromone glycoside A. The new compound was named 6-O-[β-D-xylopyranosyl-(1→6)-β-D-glucopyranosyl]-5-hydroxy-2,7-dimethyl-4H-1-benzopyran-4-one based on its structure. Table 1 shows the NMR data of the new compound.1 H-NMR and 13 C-NMR in CD3OD.

[0056] Table 1: NMR data of the novel compound kasugamycin A of this invention

[0057]

[0058] Experiment 2:

[0059] The activity of kasugamycin A prepared in Experiment 1 in promoting the immune enhancement of RAW 264.7 cells was investigated, and the steps are as follows:

[0060] 1. Drug Preparation: Kasugamycin A was dissolved in DMSO to prepare a 50 mM stock solution. It was then diluted with PBS to test concentrations of 3.125 μM, 6.25 μM, and 12.5 μM.

[0061] 2. Cell Culture

[0062] Mouse mononuclear macrophage RAW 264.7 cells were grown in DMEM medium containing 10% fetal bovine serum and cultured in suspension in an incubator with 5% CO2, saturated humidity and 37°C. Cells in the logarithmic growth phase were used for experiments.

[0063] 3. Effects of CCK-8 assay on cell proliferation

[0064] RAW 264.7 cells were grown at 3 × 10⁻⁶ cells per cell line. 4 Cells were seeded at a density of [number] cells / well in 96-well plates. After adhesion, the cells were treated with different concentrations of kasugamycin A for 24 h. The plates were then removed, the supernatant discarded, and 100 μL of complete CCK-8 cell culture medium containing 10% CCK-8 cells was added to each well. The 96-well plates were incubated for 30 min, and the absorbance (OD value) at 450 nm was measured using a microplate reader. Wells containing only CCK-8 solution and complete culture medium were designated as the complete blank group. All groups had at least three replicates to determine the safe concentration of kasugamycin A. The results showed that kasugamycin A had no cell-killing ability at the tested concentrations (3.125 μM, 6.25 μM, 12.5 μM).

[0065] 4. Griess colorimetric assay for the effect of drugs on NO secretion by cells

[0066] RAW 264.7 cells in good growth condition were seeded into sterile 96-well plates at a seeding density of 3 × 10⁶ cells / well. 4Cells / well, 100 μL of complete culture medium / well, mixed well and incubated overnight in a cell culture incubator. When the cells reach 70-80% of the bottom area of ​​the 96-well plate, remove the 96-well plate, remove the supernatant culture medium using a pipette, add 100 μL of cell culture medium to the blank control group, and add cell culture medium containing monomeric compounds at concentrations of 3.125, 6.250, and 12.50 μM to the drug-treated groups, respectively. Three replicates are set for each group, and the plates are incubated for another 24 h. After the drug effect is complete, 50 μL of cell supernatant from each well is transferred to another sterile 96-well plate. 50 μL of Griess Reagent I (diazotization reagent) and Griess Reagent II (coupling reagent) are added to each well in the dark. The absorbance at 540 nm is measured using a microplate reader. The concentration C of NO is calculated using a standard curve, and the increase rate of NO production promoted by each compound is calculated as: increase rate = (C * (Gryllium osmosis reagent) ... 给药组 – C 空白组 ) / C 空白组 The results showed that NO secretion increased by 25.0%, 1431.3%, and 2350.0% at 3.125 μM, 6.25 μM, and 12.5 μM, respectively, indicating that it has good immune-enhancing activity.

[0067] 5. ELISA kit to test the effect of drugs on cellular secretion of IL-6 and TNF-α.

[0068] RAW 264.7 cells were grown at 3 × 10⁻⁶ cells per cell line. 4 Seeds were planted at a density of 100 cells / well in 96-well plates. After adhesion, the plates were treated with different concentrations of sambroxol A for 24 h. The plates were then removed, the supernatant was collected, and the absorbance (OD value) was measured at 450 nm using a microplate reader according to the kit instructions. The concentrations C of IL-6 and TNF-α were calculated using a standard curve, and the increase rate was calculated as follows: (C0 = C0)0 给药组 – C 空白组 ) / C 空白组 The results showed that at concentrations of 3.125 μM, 6.25 μM, and 12.5 μM, the compound increased IL-6 secretion by 17.6%, 38.9%, and 92.9%, respectively, and increased TNF-α secretion by 89.8%, 170.6%, and 246.4%, respectively. This indicates that it has good immune-enhancing activity.

Claims

1. Kasugamycin A, characterized in that... The molecular formula of the kasugamycin A is C 22 H 28 O 13 The molecular structural formula is: The molecular weight is 500.

5.

2. The method for preparing kasugamycin A according to claim 1, characterized in that... The preparation method of the kasugamycin glycoside A is as follows:

1. Place the root of *Ligustrum lucidum* in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and reflux extract with 70% ethanol for 2 hours each time, for 3 times, and combine the extracts to obtain the extract; 2. Concentrate the extract obtained in step 1 until there is no alcohol odor, dilute it with water, and then load it onto a D101 macroporous resin column. Then, elute it sequentially with water, 15% (v / v), 30% (v / v), 60% (v / v) and 90% (v / v) ethanol aqueous solution.

3. The elution fraction of the 60% ethanol aqueous solution from step 2 was separated by ODS column chromatography. Elution was carried out sequentially with methanol-water solutions of 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% concentrations to obtain methanol-water eluents of different concentrations. The elution fraction of 40% methanol-water eluent from the ODS column chromatography was used to prepare a high-performance liquid chromatography (HPLC) sample. The HPLC chromatogram was prepared using 28% methanol as the mobile phase and a flow rate of 3 mL / min. The absorption peak appearing at the retention time of 23-24 min was collected, which yielded sambroside A.

3. The method for preparing kasugamycin A according to claim 2, characterized in that... The Soxhlet dynamic extraction and concentration unit described in step one is set to atmospheric pressure extraction and ambient temperature extraction.

4. The method for preparing kasugamycin A according to claim 2, characterized in that... The high-performance liquid chromatography (HPLC) chromatograms described in step three were acquired using a Waters 2535 semi-preparative HPLC system, with C0.05 as the chromatogram. 18 The reversed-phase silica gel column was used as the packing material, and the Waters 2998 DAD detector was used as the detector.

5. The application of the kasugamycin glycoside A according to claim 1, characterized in that... The kasugamycin A is used as an active ingredient in the preparation of immune-enhancing drugs.

6. The application of kasugamycin A according to claim 5, characterized in that... The dosage forms of the immune-enhancing drugs include injections, lyophilized powder injections, and oral preparations.

7. The application of kasugamycin A according to claim 6, characterized in that... The oral preparations include tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release preparations.

8. The application of kasugamycin A according to claim 5, characterized in that... The kasugamycin A, as the active ingredient of the immune-enhancing drug, is used to promote the release of NO, IL-6, and TNF-α from RAW 264.7.